Nom du produit:phenyl N-(2-aminopyrimidin-5-yl)carbamate
IUPAC Name:phenyl N-(2-aminopyrimidin-5-yl)carbamate
- CAS：2883543-45-9
- Formule moléculaire：C11H10N4O2
- Pureté：95%+
- Numéro de catalogue：CM1046374
- Poids moléculaire：230.23
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2883543-45-9
- Formule moléculaire:C11H10N4O2
- Point de fusion:-
- Code SMILES:NC1=NC=C(NC(=O)OC2=CC=CC=C2)C=N1
- Densité:
- Numéro de catalogue:CM1046374
- Poids moléculaire:230.23
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Pyrimidines
- Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Column Infos
- STX-478
- Scorpion presented initial, first-in-human clinical results from its Phase 1/2 study of STX-478 in advanced solid tumor patients in a Proffered Paper late-breaking session at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. Initial Phase 1 monotherapy data for STX-478, an oral, once-daily, mutant-selective, allosteric PI3Kα inhibitor, demonstrated potentially best-in-class PI3Kα inhibition, with anti-tumor activity observed in multiple cancer types, including HR+/HER2- breast cancer (BC), gynecological tumors, and other solid tumors. STX-478 was well-tolerated, including in pre-diabetic, diabetic and heavily pre-treated patients and showed no significant wild-type-mediated toxicities.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
